Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
High-signal headlines only — macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Can-Fite stock jumps 20% after mid-stage data show namodenoson is well tolerated in advanced pancreatic cancer patients, meeting the study's primary safety endpoint.
Health care stocks were edging up late Friday afternoon with the NYSE Health Care Index and the Stat
Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the State Street H
All three major US stock indexes were edging lower in midday trading on Friday following the Christm
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively tr